Antibody Mediated Rejection clinical trials at University of California Health
2 in progress, 1 open to eligible people
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
open to eligible people ages 18 years and up
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020
at UCLA UCSF
VIRTUUS Children's Study
Sorry, in progress, not accepting new patients
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
at UCLA UCSD
Last updated: